Medical ScopeToday, autoimmune diseases affect 5-7% of the world’s population representing the third cause of morbidity in developed countries (after cardiovascular disease and cancer). Any molecule in the body may act as an auto-antigen and induce an autoimmune reaction, meaning that the range of possible auto-antibodies to be sought is substantial. Auto-antigens may be expressed in cells distributed throughout the body (non-organ-specific diseases) or in only in a specific part of a given organ. In some pathological situations, auto-antibodies are extremely sensitive markers which can be detected months or even years before the onset of symptoms.
Activities and Techniques Biomnis can assay for more than 60 different auto-antibodies, including some that are rare or were only recently characterised.
Auto-antibodies can be detected either by indirect immunofluorescence on cell smears (transfected Hep2 cells, neutrophils) or tissue sections (pancreas, adrenal gland, oesophagus, etc.), or directly by ELISA, whereas others can be typed by immunoblotting.
Research & DevelopmentBiomnis possesses an extensive serum library and actively participates in the evaluation and validation of reagents and machines. It has also developed collaborations with University Hospital departments to characterise the clinical significance of certain auto-antibodies.